RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOLLOWING A NON-MYELOABLATIVE (NMST) CONDITIONING WITH FLUDARABINE AND LOW DOSE TBI IN PATIENTS WITH HEMATOLOCICAL MALIGNANCIES AND METASTATIC MELANOMA: A SINGLE-CENTER EXPERIENCE.
2004-01-01 Benedetti, E; Papineschi, Federico; Caracciolo, F; Galimberti, Sara; Azzarà, A; Carulli, Giovanni; Petrini, Mario
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS)
2018-01-01 Grassi, S; Palumbo, S; Mariotti, V; Ciabatti, E; Guerrini, F; Perutelli, F; Barate, C; Petrini, M; Pellegrini, S; Galimberti, S
Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.
2009-01-01 Buda, Gabriele; Martino, A; Orciuolo, E; Lupia, A; Galimberti, Sara; Gentile, M; Morabito, F; Rossi, ANNA MARIA; Petrini, Mario
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?
2013-01-01 L., Aprile; L., Puccetti; Galimberti, Sara; A., Gozzini; F., Scarpini; M., Defina; F., De Majo; C., Baratè; A., Sicuranza; V., Candi; B., Scappini; D., Raspadori; A., Gozzetti; A., Bosi; Petrini, Mario; M., Bocchia
AUTOIMMUNE DISEASES AND MYELOID HEMATOLOGICAL DISORDERS: A POSSIBLE PATHOGENETIC RELATIONSHIP
2020-01-01 Galimberti, S.; Baratè, C.; Ricci, F.; Balducci, S.; Governato, G.; Fulvio, G.; Elefante, E.; Ferro, F.; Di Paolo, A.; Baglietto, L.; Petrini, M.; Baldini, C.
AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVE OUTCOME IN NON-HODGKIN'S LYMPHOMA: RESULTS OF A COMPUTER SCIENCE ANALYSIS.
2010-01-01 Pelosini, M; Baronti, F; Galimberti, Sara; Caracciolo, F; Benedetti, E; Papineschi, Federico; Starita, A; Petrini, Mario
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN DIFFUSE-LARGE B CELL LYMPHOMA: THE TUSCANY EXPERIENCE
2015-01-01 Iovino, Lorenzo; Donnini, I.; Rigacci, L.; Puccini, Benedetta; Kovalchuk, S.; Orciuolo, E.; Mazziotta, F.; Fabbri, A.; Cencini, E.; Bocchia, M.; Petrini, M.; Bosi, A.
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA: THE TUSCANY EXPERIENCE
2015-01-01 Iovino, L; Donnini, I.; Rigacci, L.; Orciuolo, E.; Puccini, B.; Kovalchuk, S.; Rigacci, L.; Mazziotta, F.; Puccini, B.; Fabbri, A.; Cencini, E.; Bocchia, M.; Petrini, M.; Bosi, A.
BORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES
2008-01-01 Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario
Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells
2008-01-01 Savli, H.; Galimberti, Sara; Canestraro, M.; Nagy, B.; Palumbo, Ga; Petrini, Mario
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOLLOWING A NON-MYELOABLATIVE (NMST) CONDITIONING WITH FLUDARABINE AND LOW DOSE TBI IN PATIENTS WITH HEMATOLOCICAL MALIGNANCIES AND METASTATIC MELANOMA: A SINGLE-CENTER EXPERIENCE. | 1-gen-2004 | Benedetti, E; Papineschi, Federico; Caracciolo, F; Galimberti, Sara; Azzarà, A; Carulli, Giovanni; Petrini, Mario | |
| Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) | 1-gen-2018 | Grassi, S; Palumbo, S; Mariotti, V; Ciabatti, E; Guerrini, F; Perutelli, F; Barate, C; Petrini, M; Pellegrini, S; Galimberti, S | |
| Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B. | 1-gen-2009 | Buda, Gabriele; Martino, A; Orciuolo, E; Lupia, A; Galimberti, Sara; Gentile, M; Morabito, F; Rossi, ANNA MARIA; Petrini, Mario | |
| Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? | 1-gen-2013 | L., Aprile; L., Puccetti; Galimberti, Sara; A., Gozzini; F., Scarpini; M., Defina; F., De Majo; C., Baratè; A., Sicuranza; V., Candi; B., Scappini; D., Raspadori; A., Gozzetti; A., Bosi; Petrini, Mario; M., Bocchia | |
| AUTOIMMUNE DISEASES AND MYELOID HEMATOLOGICAL DISORDERS: A POSSIBLE PATHOGENETIC RELATIONSHIP | 1-gen-2020 | Galimberti, S.; Baratè, C.; Ricci, F.; Balducci, S.; Governato, G.; Fulvio, G.; Elefante, E.; Ferro, F.; Di Paolo, A.; Baglietto, L.; Petrini, M.; Baldini, C. | |
| AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVE OUTCOME IN NON-HODGKIN'S LYMPHOMA: RESULTS OF A COMPUTER SCIENCE ANALYSIS. | 1-gen-2010 | Pelosini, M; Baronti, F; Galimberti, Sara; Caracciolo, F; Benedetti, E; Papineschi, Federico; Starita, A; Petrini, Mario | |
| AUTOLOGOUS-STEM CELL TRANSPLANTATION IN DIFFUSE-LARGE B CELL LYMPHOMA: THE TUSCANY EXPERIENCE | 1-gen-2015 | Iovino, Lorenzo; Donnini, I.; Rigacci, L.; Puccini, Benedetta; Kovalchuk, S.; Orciuolo, E.; Mazziotta, F.; Fabbri, A.; Cencini, E.; Bocchia, M.; Petrini, M.; Bosi, A. | |
| AUTOLOGOUS-STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA: THE TUSCANY EXPERIENCE | 1-gen-2015 | Iovino, L; Donnini, I.; Rigacci, L.; Orciuolo, E.; Puccini, B.; Kovalchuk, S.; Rigacci, L.; Mazziotta, F.; Puccini, B.; Fabbri, A.; Cencini, E.; Bocchia, M.; Petrini, M.; Bosi, A. | |
| BORTEZOMIB COMBINED WITH HISTONE DEACETYLASE INHIBITOR ITF2357 OR ARSENIC TRIOXIDE EXERTS SYNERGISTIC ANTI-PROLIF- ERATIVE AND PRO-APOPTOTIC EFFECTS IN P39 CELL LINE: A POSSI- BLE NEW APPROACH TO HIGH-RISK MYELODYSPLASTIC SYNDROMES | 1-gen-2008 | Galimberti, Sara; Canestraro, M; Savli, H; Palumbo, Ga; Nagy, B; Di Raimondo, F; Petrini, Mario | |
| Bortezomib combined with histone deacetylase inhibitor ITF2357 or arsenic trioxide exerts aynergistic anti-proliferative and pro-apoptotic effect on P39 cells | 1-gen-2008 | Savli, H.; Galimberti, Sara; Canestraro, M.; Nagy, B.; Palumbo, Ga; Petrini, Mario |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 1 Contributo su Rivista 101
- 1 Contributo su Rivista::1.5 Abst... 101
Data di pubblicazione
- 2010 - 2020 48
- 2000 - 2009 49
- 1990 - 1999 4
Rivista
- BLOOD 35
- HAEMATOLOGICA 33
- BONE MARROW TRANSPLANTATION 13
- HAEMATOLOGICA 7
- BONE MARROW TRANSPLANTATION 4
- AMERICAN JOURNAL OF CLINICAL ONCO... 2
- ANNALS OF THE RHEUMATIC DISEASES 1
- BLOOD REVIEWS 1
- CYTOMETRY. PART A 1
- EUROPEAN SURGICAL RESEARCH 1
Keyword
- immune reconstitution 3
- immunotherapy 2
- T-lymphocytes 2
- thymus 2
- zinc 2
- 10 patients died all due to progr... 1
- 27 a partial remission considerin... 1
- 28 with 70 mg/m2 and 5 with 120 m... 1
- 3 relapsed and 28 with disease un... 1
- 31 in continuous complete remission 1
Lingua
- eng 71
Accesso al fulltext
- no fulltext 96
- open 4
- restricted 1